Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C5H4FN3O2 |
| Molecular Weight | 157.1026 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)C1=NC(F)=CNC1=O
InChI
InChIKey=ZCGNOVWYSGBHAU-UHFFFAOYSA-N
InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
| Molecular Formula | C5H4FN3O2 |
| Molecular Weight | 157.1026 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Favipiravir (originally known as T-705) is an orally administered novel anti-viral compound with a unique mechanism of action that is active against a wide range of RNA-based viruses in laboratory tests. Favipiravir has recently being approved in Japan under the brand name Avigan. Avigan is an experimental antiviral drug being developed by Toyama Chemical of Japan. It is a viral RNA polymerase inhibitor with a new mechanism of action, inhibiting viral gene replication within infected cells to prevent the propagation. Favipiravir is
phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl-5′- triphosphate (RTP). Favipiravir is active against a broad range of influenza viruses, including
A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus. It also inhibits
influenza strains resistant to current antiviral drugs, and shows a synergistic effect in combination
with oseltamivir, thereby expanding influenza treatment options. A Phase III clinical evaluation of
favipiravir for influenza therapy has been completed in Japan and two Phase II studies have been
completed in the United States. In addition to its anti-influenza activity, favipiravir blocks the
replication of many other RNA viruses, including arenaviruses (Junin, Machupo and Pichinde);
phleboviruses (Rift Valley fever, sandfly fever and Punta Toro); hantaviruses (Maporal, Dobrava,
and Prospect Hill); flaviviruses (yellow fever and West Nile); enteroviruses (polio- and
rhinoviruses); an alphavirus, Western equine encephalitis virus; a paramyxovirus, respiratory
syncytial virus; and noroviruses.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL612610 |
0.19 µM [EC50] | ||
Target ID: CHEMBL612765 |
0.083 µM [EC50] | ||
Target ID: CHEMBL2366902 |
0.5 µM [EC50] | ||
Target ID: CHEMBL613845 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | AVIGAN Approved UseTreatment of novel or re-emerging pandemic influenza virus infections (limited to cases in which
other influenza antiviral drugs are ineffective or not sufficiently effective). Launch Date2014 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
15.58 μg/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7.18 μg/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
44.24 μg/mL |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
40.29 μg/mL |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
1.39 μg/mL |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.06 μg/mL |
90 mg single, oral dose: 90 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
8.39 μg/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
16.59 μg/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
33.35 μg/mL |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
78.61 μg/mL |
1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
83.62 μg/mL |
2000 mg single, oral dose: 2000 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
92.17 μg/mL |
2400 mg single, oral dose: 2400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
17.24 μg/mL |
400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
36.15 μg/mL |
400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
43.83 μg/mL |
400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
18.52 μg/mL |
400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
21.88 μg/mL |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
36.24 μg/mL |
600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
36.23 μg/mL |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
23 μg/mL |
600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
31.88 μg/mL |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
16.97 μg/mL |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
25.56 μg/mL |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
51.6 μg/mL |
1200 mg 2 times / day multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
40.55 μg/mL |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
43.04 μg/mL |
1200 mg 2 times / day multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
61.49 μg/mL |
600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
35.9 μg/mL |
1200 mg 2 times / day multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
57.6 μg/mL |
800 mg 2 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
42.11 μg × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
36.64 μg × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
280.95 μg × h/mL |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
271.58 μg × h/mL |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
2.58 μg × h/mL |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
9.23 μg × h/mL |
90 mg single, oral dose: 90 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
19.67 μg × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
39.41 μg × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
113.15 μg × h/mL |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
538.42 μg × h/mL |
1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1093.62 μg × h/mL |
2000 mg single, oral dose: 2000 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1297.56 μg × h/mL |
2400 mg single, oral dose: 2400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
50.02 μg × h/mL |
400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
381.57 μg × h/mL |
400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
460.49 μg × h/mL |
400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
43.66 μg × h/mL |
400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
81.87 μg × h/mL |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
91.4 μg × h/mL |
600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
215.05 μg × h/mL |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
74.57 μg × h/mL |
600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
153.07 μg × h/mL |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
45.55 μg × h/mL |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
151.46 μg × h/mL |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
475.22 μg × h/mL |
1200 mg 2 times / day multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
504.87 μg × h/mL |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
203.87 μg × h/mL |
1200 mg 2 times / day multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
805.28 μg × h/mL |
600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
346 μg × h/mL |
1200 mg 2 times / day multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
957 μg × h/mL |
800 mg 2 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.8 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.7 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
3.4 h |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.2 h |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
|
1.3 h |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.5 h |
90 mg single, oral dose: 90 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.5 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.6 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.2 h |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.9 h |
1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.3 h |
2000 mg single, oral dose: 2000 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.5 h |
2400 mg single, oral dose: 2400 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.1 h |
400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
8.7 h |
400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.2 h |
400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.8 h |
400 mg 3 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.7 h |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.2 h |
600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.7 h |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.1 h |
600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3.1 h |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.8 h |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3.3 h |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7 h |
1200 mg 2 times / day multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6.7 h |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3 h |
1200 mg 2 times / day multiple, oral dose: 1200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.8 h |
600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
FAVIPIRAVIR plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
45.6% |
FAVIPIRAVIR serum | Homo sapiens |
Doses
| Dose | Population | Adverse events |
|---|---|---|
200 mg 2 times / day steady-state, oral Studied dose Dose: 200 mg, 2 times / day Route: oral Route: steady-state Dose: 200 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: gastrointestinal, hyperuricaemia... Other AEs: gastrointestinal (14 patients) Sources: hyperuricaemia (3 patients) |
3000 mg 2 times / day steady-state, oral Studied dose Dose: 3000 mg, 2 times / day Route: oral Route: steady-state Dose: 3000 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: gastrointestinal, hyperuricaemia... Other AEs: gastrointestinal (25 patients) Sources: hyperuricaemia (7 patients) |
600 mg 2 times / day steady-state, oral Studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady-state Dose: 600 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Diarrhea, Liver injury... Other AEs: Diarrhea (2 patients) Sources: Liver injury (1 pt) kidney injury (1 pt) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| gastrointestinal | 14 patients | 200 mg 2 times / day steady-state, oral Studied dose Dose: 200 mg, 2 times / day Route: oral Route: steady-state Dose: 200 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| hyperuricaemia | 3 patients | 200 mg 2 times / day steady-state, oral Studied dose Dose: 200 mg, 2 times / day Route: oral Route: steady-state Dose: 200 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| gastrointestinal | 25 patients | 3000 mg 2 times / day steady-state, oral Studied dose Dose: 3000 mg, 2 times / day Route: oral Route: steady-state Dose: 3000 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| hyperuricaemia | 7 patients | 3000 mg 2 times / day steady-state, oral Studied dose Dose: 3000 mg, 2 times / day Route: oral Route: steady-state Dose: 3000 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Liver injury | 1 pt | 600 mg 2 times / day steady-state, oral Studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady-state Dose: 600 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| kidney injury | 1 pt | 600 mg 2 times / day steady-state, oral Studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady-state Dose: 600 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Diarrhea | 2 patients | 600 mg 2 times / day steady-state, oral Studied dose Dose: 600 mg, 2 times / day Route: oral Route: steady-state Dose: 600 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| In vitro and in vivo activities of anti-influenza virus compound T-705. | 2002 Apr |
|
| In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. | 2003 Sep |
|
| Mechanism of action of T-705 against influenza virus. | 2005 Mar |
|
| Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. | 2008 |
|
| Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. | 2008 Dec |
|
| Developing new antiviral agents for influenza treatment: what does the future hold? | 2009 Jan 1 |
|
| T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. | 2009 Jun |
|
| Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. | 2009 Oct |
|
| Antiviral strategies for pandemic and seasonal influenza. | 2010 Aug |
|
| Combination chemotherapy for influenza. | 2010 Aug |
|
| Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. | 2010 Aug 26 |
|
| Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase. | 2010 Dec 21 |
|
| A Potent, Broad-Spectrum Antiviral Agent that Targets Viral Membranes. | 2010 May |
|
| Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. | 2010 May |
|
| Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. | 2010 Oct 7 |
|
| [Present and future in development of new anti-influenza drugs]. | 2010 Sep |
|
| Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog. | 2010 Sep 16 |
Sample Use Guides
The usual adult dosage is 1600 mg of favipiravir administered orally twice daily on Day 1,
followed by 600 mg orally twice daily from Day 2 to Day 5. The total treatment duration should
be 5 days.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:45:53 GMT 2025
by
admin
on
Wed Apr 02 07:45:53 GMT 2025
|
| Record UNII |
EW5GL2X7E0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C281
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
||
|
NCI_THESAURUS |
C25995
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Favipiravir
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
259793-96-9
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
C462182
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
134722
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
Favipiravir
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
492405
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
BC-05
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
DB12466
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
AVIGAN
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | APPROVED MARCH 2014 | ||
|
100000180049
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
EW5GL2X7E0
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
8916
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
C81605
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
m11863
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
4887
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
CHEMBL221722
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY | |||
|
DTXSID60948878
Created by
admin on Wed Apr 02 07:45:53 GMT 2025 , Edited by admin on Wed Apr 02 07:45:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
ANALOGUE->PARENT | |||
|
TARGET ORGANISM->INHIBITOR |
DRUG APPROVED IN CHINA FOR COVID-19. Prodrug that InhibitS the RNA-dependent RNA polymerase after activation to triphosphate.
|
||
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE ACTIVE -> PRODRUG | |||
|
METABOLITE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Tmax | PHARMACOKINETIC |
|
IN HEALTHY JAPANESE VOLUNTEERS |
|
||
| Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||